Torsten Haferlach, MD1, Alexander Kohlmann, PhD1, Giuseppe Basso, MD1*, Marie-Christine Béné, PhD1*, Sabina Chiaretti, MD1*, James R. Downing, MD2, Jesús-María Hernández, MD1*, Wolf-Karsten Hofmann, MD1*, Thomas J. Kipps, MD, PhD3, Evelyn S Koay, MD4*, Geertruy Te Kronnie, PhD1, Wei-min Liu, PhD5*, Elizabeth MacIntyre, PhD1*, Ken I Mills, PhD1, Peter Papenhausen, PhD6, Claude Preudhomme, PhD1, Laura Z Rassenti, PhD7, Sheila A Shurtleff, PhD2*, John De Vos, PhD1*, Allen E Yeoh, MD4*, P. Mickey Williams, PhD5, Lothar Wieczorek, PhD5* and Robert Foŕ, MD1
1MILE Study Group, on Behalf of European LeukemiaNet (ELN, WP13), Munich, Germany
2Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN
3Moores UCSD Cancer Center, CLL Research Consortium, La Jolla, CA
4Department of Paediatrics, National University of Singapore, Singapore
5Roche Molecular Systems, Inc., Pleasanton, CA
6Laboratory Corporation of America, Research Triangle Park, NC
7UCSD, Moores Cancer Center, La Jolla, CA